| Literature DB >> 33384386 |
Yaqiong Zhou1, Dan Wang1, Licheng Jiang1, Fei Ran1, Sichao Chen1, Peng Zhou2, Peijian Wang2.
Abstract
OBJECTIVES: Accurate subtype classification in primary aldosteronism (PA) is critical in assessing the optimal treatment options. This study aimed to evaluate the diagnostic accuracy of adrenal imaging for unilateral PA classification.Entities:
Keywords: cardiology; endocrine tumours; hypertension
Mesh:
Year: 2020 PMID: 33384386 PMCID: PMC7780716 DOI: 10.1136/bmjopen-2020-038489
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow diagram of the review process. AVS, adrenal vein sampling.
Study characteristics
| Study, year | Location | Male (%) | Age (years) | Sample | Imaging methodology | Contrast used | AVS characteristics | Screening test for PA (ng/ml) | Confirmatory test for PA |
| Li | China | 61 (50) | 48.5 | 122 | CT | yes | without ACTH SI ≥2 LI≥2 | ARR | Captopril test or salt-loading test |
| Campbell | USA | 45 (61) | 55.6 | 74 | CT or MRI | no | with ACTH, SI≥5, LI≥4 | not ARR | no |
| Aono | Japan | NA | 56 | 317 | CT | no | with ACTH, SI>2, LI≥2 | ARR >20 | Captopril test, furosemide upright test or salt-loading test |
| Sam | Canada | 201 (59) | 52.1 | 342 | CT or MRI | yes | with ACTH, SI>2, LI≥4 | ARR | no |
| Umakoshi | Japan | 762 (47.9) | 53 | 1591 | CT | yes | with ACTH, SI>5, LI>4 | ARR | Captopril test, furosemide upright test or salt-loading test |
| Nanba | USA | 87 (59) | 54 | 147 | CT | no | with ACTH, SI≥5, LI≥4 | ARR | Salt-loading test |
| Kamemura | Japan | 177 (45) | 54 | 393 | CT | no | with ACTH, SI>5, LI>4 | ARR | Captopril test, furosemide upright test or salt-loading test |
| Zhu | China | NA | 46 | 394 | CT | no | without ACTH, SI≥3, LI≥2 | ARR | Fludrocortisone test or salt-loading test |
| Pedersen | Denmark | 24 (54) | 51 | 45 | CT or MRI | no | without ACTH. SI /LI NA | ARR | Fludrocortisone test or postural test |
| Kocjan | Slovenia | 46 (69) | 56 | 67 | CT | no | with ACTH, SI>5, LI>4 | ARR | Salt-loading test |
| Asmar | USA | 148 (63) | 55 | 235 | CT or MRI | no | with ACTH, SI≥5, LI≥4 | ARR | no |
| Riester | Germany | NA | 35 | 28 | CT or MRI | no | without ACTH, SI≥2, LI≥4 | ARR | Salt-loading test |
| Sze | UK | 42 (56) | 50.5 | 75 | CT | yes | with ACTH, SI≥5, LI≥4 | not ARR | salt-loading test |
| Kűpers | France | 53 (61) | 46 | 87 | CT | no | with ACTH, SI≥2, LI≥4 | ARR | Salt-loading test |
| Lau | UK | 24 (64) | 51.8 | 39 | CT | no | with ACTH, SI≥5, LI≥4 | not ARR | salt-loading test |
| Burton | UK | NA | 50.9 | 40 | CT | Yes | without ACTH, LI≥4 | not ARR | no |
| Salem | UK | 16 (44) | 44.7 | 38 | CT | no | without ACTH, LI≥4 | ARR | Salt-loading test |
| Oh | Korea | 45 (52) | 50.7 | 86 | CT | yes | with ACTH, SI≥3, LI>4 | ARR | Salt-loading test |
| Sarlon-Bartoli | France | NA | 52 | 58 | CT | yes | without ACTH, SI≥1, LI>2 | ARR | no |
| Mathur | USA | 63 (55) | 50.6 | 114 | CT | no | with ACTH, SI>2, LI≥4 | ARR | Captopril test, posture test or salt-loading test |
| Mulatero | Italy | NA | 52.4 | 70 | CT | yes | 65 with ACTH; five without ACTH, SI>2, LI≥4 | ARR | Salt-loading test |
| Minami | Japan | 12 (34) | 54 | 35 | CT | no | with ACTH SI /LI NA | ARR | Salt-loading test |
| Nwariaku | USA | 27 (67) | 51 | 40 | CT | yes | with ACTH, SI≥3, LI>4 | ARR | Captopril test or posture test |
| Young | USA | 163 (84) | 53 | 194 | CT | no | with ACTH, SI>5, LI>4 | ARR | Salt-loading test |
| Magill | USA | 27 (71) | 51 | 38 | CT | no | with ACTH, SI≥3, LI≥4 | ARR | Salt-loading test |
ACTH, adrenocorticotropic hormone; ARR, aldosterone-to-renin ratio; AVS, adrenal vein sampling; LI, lateralisation index; NA, not available; PA, primary aldosteronism; SI, selectivity index.
Figure 2Assessment of methodological quality of included studies using the QUADAS-2 Criteria. Stacked bars represent the proportion of studies with a high (red), or unclear (yellow) or low (green) risk of bias and applicability concerns. QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2 criteria.
Pooled summary results by subgroups
| Subgroups | No of studies | Sensitivity (95% CI) | Sensitivity with I2, % | Specificity (95% CI) | Specificity with I2, % |
| Total | 25 | 68 (61 to 74) | 86.9% | 57 (50 to 65) | 86.9 |
| Age | |||||
| | |||||
| >40 years | 21 | 68 (60 to 75) | 87.4% | 57 (49 to 64) | 87.4 |
| AVS procedure | |||||
| With ACTH | 17 | 66 (57 to 73) | 86.5% | 56 (46 to 65) | 90.5 |
| Without ACTH | 7 | 70 (58 to 79) | 90.3% | 60 (45 to 74) | 79.2 |
| Cutoff values of LI | |||||
| LI≥2 | 4 | 61 (37 to 80) | 95.5% | 54 (38 to 68) | 88.3 |
| LI≥4 | 18 | 69 (62 to 75) | 76.4% | 59 (50 to 68) | 89.0 |
| Screening test for PA | |||||
| ARR | 21 | 66 (58 to 72) | 87.7% | 58 (50 to 65) | 86.2 |
| | |||||
| Confirmatory test for PA | |||||
| Salt-loading test | 12 | 71 (62 to 80) | 78.6% | 60 (49 to 70) | 74.9 |
| Additional options | 8 | 57 (46 to 67) | 90.6% | 66 (60 to 72) | 66 |
| No | 5 | 72 (64 to 79) | 55.8% | 42 (24 to 63) | 90.3 |
| Imaging methodology | |||||
| CT | 20 | 67 (59 to 74) | 88.6% | 60 (53 to 67) | 82.5 |
| Contrast CT | 8 | 77 (66 to 85) | 86.4% | 60 (49 to 69) | 82.2 |
| Nocontrast CT | 12 | 58 (49 to 66) | 83.8% | 60 (51 to 68) | 81.8 |
| CT/MRI | 5 | 69 (62 to 76) | 30% | 45 (27 to 64) | 87.9 |
| Quality of studies | |||||
| High-quality studies | 13 | 78 (73 to 83) | 48.6% | 51 (39 to 63) | 78.6 |
| Unclear-quality studies | 6 | 62 (58 to 65) | 0% | 62 (54 to 70) | 85.1 |
| Low-quality studies | 6 | 44 (38 to 50) | 46.4% | 69 (60 to 78) | 69.2 |
| Sample size | |||||
| ≥100 | 10 | 59 (51 to 67) | 90.6% | 58 (49 to 66) | 92.1 |
| <100 | 15 | 74 (67 to 81) | 71.3% | 60 (47 to 71) | 78.1 |
| Outlier excluded | 20 | 65 (60 to 70) | 77.1% | 59 (52 to 66) | 85.2 |
ACTH, adrenocorticotropic hormone; ARR, aldosterone-to-renin ratio; AVS, adrenal vein sampling; LI, lateralisation index; PA, primary aldosteronism.